title: Iloprost added to the cardioplegic solutions improves myocardial performance.
abstract: A total of 12 mongrel dogs were divided into two equal groups. Six animals received IIoprost and the other 6 animals did not receive any additional treatment. In the Iloprost group, Iloprost was added to the cardioplegic solution (25 ng). Also, Iloprost was used (10 ng/kg/min.) 5 min. before and after cross-clamping. All cardiac output and biochemical measurements were evaluated before cross-clamp and 15 min., 1 h, and 4 h after cross-clamp. The measured dp/dt shows that the hearts treated with Iloprost preserved left ventricular function. Comparison of contractility indices between the groups revealed that contractile recovery was 59% in the control group and 71% in the Iloprost group (p < 0.05). Tumor necrosis factor (TNF) alpha level was significantly elevated in the control group (p < 0.001). Its level was 22.2 +/- 2.2 pg/mL in the control group and 13.8 +/- 1.0 pg/mL in the Iloprost group. E- and P-selectin levels were elevated in the control group (p < 0.001). ICAM-1 level was also elevated in the control group. ICAM-1 level was 17.7 +/- 1.8 ng/mL in the control group and 8.5 +/- 1.8 ng/mL in the Iloprost group. The Iloprost that was added to the cardioplegic solution and low dose administration during the pre- and post-ischemic period inhibits the toxic mediator release from endothelium-leukocyte interaction and reduces the severity of ischemia-reperfusion injury.
authors.affiliation: Cardiovascular Surgery Department of Türkiye Yüksek Ihtisas Hospital of Ankara, Turkey.
authors.forename: S F
authors.initials: SF
authors.lastname: Katircioğlu
authors.forename: Z
authors.initials: Z
authors.lastname: Saritaş
authors.forename: A T
authors.initials: AT
authors.lastname: Ulus
authors.forename: B
authors.initials: B
authors.lastname: Yamak
authors.forename: D
authors.initials: D
authors.lastname: Yücel
authors.forename: S
authors.initials: S
authors.lastname: Ayaz
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D004285:Dogs; D006439:Hemodynamics; D016285:Iloprost / Q000494:pharmacology*; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000378:metabolism; D019007:P-Selectin / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D002314:Cardioplegic Solutions; D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D014409:Tumor Necrosis Factor-alpha; D014665:Vasodilator Agents; D000244:Adenosine Diphosphate; D016285:Iloprost